The Macfarlane Burnet Institute for Medical Research and Public Health Limited

Hepgenics Pty Ltd.

The Macfarlane Burnet Centre for Medical Research Limited

Artes Biotechnology Gmbh

Biopoint Hong Kong Ltd

David Andrew Anderson

Mary Louise Garcia

Fan Li

Alan Lee Landay

Suzanne Crowe

Stephen Alistair Logarnini

Nadine Carmel Barnes

Khayriyyah Mohd Hanafiah

Zhuang Hui

Joseph Torresi

Damian Francis John Purcell

Elizabeth Vera Ludmila Grgacic

Katherine Anders

Anne Healy

Teresa Sylvia Howard

Suzanne Mary Crowe

Robyn Elizabeth Lloyd

Clovis Palmer

Zhimei Zhang

Elizabeth Vera Ludmilla Grgacic

The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM.

Diagnostic, prognostic, therapeutic and screening protocols

The invention provides kits and methods for detecting or monitoring the number of cells in sample. The cell comprises a cell surface associated protein (CSAP) comprising a cytoplasmic (cytosolic) and an extracellular (ecto) domain. The kit comprises: (i) a chromatographic device; and (ii) a CSAP-binding agent. The method comprises: (i) optionally contacting the sample with an agent capable of lysing or permeabilizing CSAP bearing cells; (ii) contacting the sample with a CSAP-binding agent that binds to the cytoplasmic domain of the CSAP; and (iii) directly or indirectly evaluating the level or presence of bound CSAP in the sample.

Method of diagnosis and kit therefor

This invention is directed to diagnostic methods detecting the presence of an antibody to a virus in a sample from a subject and kits for using the methods.

The present invention provides a virus-like particle (VLP) comprising i) a polypeptide comprising a polypeptide of interest (POI) and at least a particle-associating portion of a large envelope (L) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof, and ii) a small envelope (S) polypeptide of an avian hepadnavirus or a functional derivative or homolog thereof. By introducing one or more POIs into the L polypeptide, the POI is translocated along with L into a particle structure made up primarily of S polypeptide. The present invention furthermore provides methods for producing a recombinant virus-like particle.

Viral vectors expressing fusion of viral large envelope protein and protein of interest

A method for enhancing an immune response to a nucleic acid vaccine comprising administering to an animal a nucleic acid construct encoding a fusion protein comprising a processing component and an antigenic polypeptide of interest wherein said processing component provides heterogeneous processing of the antigenic polypeptide when the nucleic acid construct is expressed in a host cell and a resulting enhancement of the immune response. The processing component is derived from an N-terminal portion of PORF2 of Hepatitis E virus.

Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide

The present invention relates generally to molecules such as peptides, polypeptides and proteins which carry epitopes and in particular B cell epitopes from antigenic proteins encoded by Hepatitis E Virus. These molecules are selectively immunoreactive to convalescent and/or acute phase circulating antibodies to the Hepatitis E Virus and are useful in the development of diagnostic therapeutical and prophylactic agents for Hepatitis E Virus.

Immunoreactive antigens of Hepatitis E Virus

Growing community of inventors

Brunswick, Australia

David Andrew Anderson